PTC Therapeutics (PTCT) said Monday that it signed an exclusive global license and collaboration agreement for its PTC518 Huntington's disease program with a subsidiary of Novartis (NVS), and will receive a $1 billion upfront payment.
The company said it will also be entitled to additional payments of up to $1.9 billion based on development, regulatory and sales milestones, plus a profit share in the US and double-digit tiered royalties on international sales.
As part for the deal, PTC Therapeutics said Novartis will be in charge of PTC518's development, manufacturing and commercialization after the completion of the ongoing placebo-controlled portion of a phase 2 trial on PTC518, which is expected in the first half of 2025.
The transaction is expected to close in Q1 2025, said PTC Therapeutics.
PTC Therapeutics shares were up over 20% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.